Difference between revisions of "Team:Oxford/Experiments"

Introduction

Our enzymatic approach to the treatment of urinary tract infections (UTIs) is centred on the design of a "pathogen killing" engineered microbial host containing three key features:

• Constant secretion of biofilm-degrading enzymes - degrading the biofilms of the pathogenic bacteria reduces their resistance towards antibiotics
• Production and intracellular accumulation of enzymes that can kill both the pathogenic bacteria and our engineered microbial host upon release into the extracellular medium
• A quorum sensing mechanism that triggers the release of the antibacterial enzymes in the presence of pathogenic bacteria

Due to constraints in time and resources, we focused our experimental efforts towards the development of proof-of-concepts for only the first two features.

Through our experimental work with secretion assays, biofilm assays, and cell-killing assays we were able to obtain preliminary in vitro data suggesting that the BioBrick parts which we designed to allow our microbial host to produce the relevant biofilm-degrading enzymes and bacteria-killing enzymes are indeed able to function as expected, exerting antibiofilm and bactericidal activity against bacterial strains closely related by species and/or genus to the pathogens involved in catheter-associated urinary tract infections.

Bacterial Strains and Growth Cultures

E. coli DH5α was used for all cloning purposes. The E. coli strains MG1655 and RP437 ∆FliC, as well as the multi-effector knockout BSL-1 strain of Y. enterocolitica, IML421asd, were used as expression hosts. Cultures for cloning were grown in antibiotic-supplemented Lysogeny Broth (LB) at 37°C. The E. coli expression host cultures were grown in antibiotic-supplemented Lysogeny Broth (LB) at 37°C, while cultures of Y. enterocolitica IML421asd were grown in Brain Heart Infusion (BHI) media supplemented with diaminopimelic acid (DAP) and the appropriate antibiotic at 30°C.

Bacterial cultures were grown overnight (16-20 hours) to stationary phase before being subcultured for characterization experiments.

Plasmid Construction & Gene Cloning

Each gene sequence for our parts was directly synthesized pre-fused with 1) a sequence coding for a hexahistidine tag downstream of it, and 2) the BioBrick prefix and suffix sequences containing the EcoRI/XbaI and SpeI/PstI restriction sites attached upstream and (further) downstream of it respectively through IDT. The sequences were amplified using PCR and inserted into the pSB1C3 BioBrick standard vector backbone before subsequently being cloned into E. coli DH5α for plasmid storage and submission to the Registry.

For gene expression studies, our parts, contained in the pSB1C3 backbone, were extracted via Miniprep. The NcoI restriction site was introduced upstream of each of our gene sequences (except BBa_K1659501 and BBa_K1659601) via PCR to facilitate their insertion into the arabinose-inducible pBAD/HisB commercial expression vector, and the insert-containing expression vectors were subsequently cloned separately into the standard laboratory E. coli K-12 strain MG1655 as well as a chemotaxis knockout strain E. coli RP437 ∆FliC.

In the later stages of experimentation, BBa_K1659003[pBAD] was also cloned into Y. enterocolitica IML421asd for further characterization of gene expression.

Biofilm-degrading Enzymes

According to the design requirements, our genetic constructs coding for biofilm-degrading enzymes need to achieve the following:

• Trigger the production of biofilm-degrading enzymes and facilitate the secretion of said enzymes from the expression hosts
• Ensure that the enzymes, after secretion into the extracellular medium, are still correctly folded such that they retain their enzymatic biofilm-degrading function

The parts which we characterized for this section of the design are BBa_K1659211 (DsbA-DspBx) and BBa_K1659301 (DsbA-DNase).